Form 4: Merck Director Thomas H. Glocer Reports Stock and Phantom Stock Transactions

Director Thomas H. Glocer of Merck & Co., Inc. reported the disposition of 5,100 common stock shares and the acquisition of 490.0483 phantom stock units.

Summary

• Thomas H. Glocer, a director at Merck & Co., Inc., filed a Form 4 disclosing changes in his beneficial ownership of the company's securities.
• The transactions occurred on December 31, 2024.
• Mr. Glocer disposed of 5,100 shares of common stock.
• He also acquired 490.0483 phantom stock units, which are to be settled in cash upon his termination of service.
• The phantom stock units are valued at $99.48 per unit.
• Mr. Glocer's holdings include shares acquired through dividend reinvestment transactions.
• Following these transactions, Mr. Glocer beneficially owns 98,246.6689 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a director, which is neither positive nor negative in itself.

Industry Context

This is a routine filing related to a director's stock transactions, which is common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as required by the SEC.
• The transactions reported are typical for directors who receive stock-based compensation and participate in dividend reinvestment programs.
• The reporting of phantom stock units is also a common practice for deferred compensation plans.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to a single director's holdings.
• The filing provides transparency to the market regarding insider trading activities.

Key Dates

Keywords

Form 4, Merck, Director, Thomas H. Glocer, Stock Transaction, Phantom Stock, Beneficial Ownership, SEC Filing